Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Proteasome Inhibitors Market Valued at Present and by 2029?

In the past few years, the market size of proteasome inhibitors has notably expanded. Anticipated growth is from $2.01 billion in 2024 to $2.17 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.9%. This surge in the historical period owes its success to scientific advancements, medical studies and tests, FDA consent, an increase in cancer instances, and improvements in medication distribution.

Expectations are high for considerable expansion in the proteasome inhibitors market size in the upcoming years. Anticipated to climb to “$3.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%.” The projected growth during this period is credited to factors such as precision medicine strategies, the development of next-gen inhibitors, improvements in healthcare infrastructure, combined targeted therapies, and the embracing of emerging markets. Coming trends expected during the forecast period are combinations of immunotherapy, selective proteasome impediment, inhibitors with extended half-lives, oral formulations, and treatments for resistant cancer variants.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12251&type=smp

#What Drivers Are Influencing Growth In The Proteasome Inhibitors Market?

The rise in the incidence of pancreatic cancer is anticipated to spur the growth of the proteasome inhibitors market. This specific cancer form originates in the pancreas cells, an essential organ nestled in the abdomen behind the stomach. Proteasome inhibitors, primarily utilized to counter pancreatic cancer, prove instrumental as the proteasome is key in fostering cell growth and survival by breaking down proteins managing cell cycle advancement and cellular death. This process hinders the survival of cancer cells and restricts tumor growth and metastasis. For example, in January 2024, American Cancer Society, a health organization based in the US, stated in its report that around 64,050 adults in the US were detected with pancreatic cancer by 2023, resulting in 50,550 fatalities. Moreover, this figure saw a swell to 66,440, with the death toll touching 51,750. Thus, the escalating occurrence rate of pancreatic cancer is fueling the growth of the proteasome inhibitors market.

The proteasome inhibitors market covered in this report is segmented –

1) By Product: Velcade, Kyprolis, Ninlaro, Other Products

2) By Drugs: Bortezomib, Carfilzomib, Ixazomib

3) By Indication: Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospital, Specialty Clinics, Other End-Users

Subsegments:

1) By Velcade: Injectable Velcade (Bortezomib), Oral Formulations

2) By Kyprolis: Injectable Kyprolis (Carfilzomib), Combination Therapies With Kyprolis

3) By Ninlaro: Oral Ninlaro (Ixazomib), Combination Therapies With Ninlaro

4) By Other Products: Investigational Proteasome Inhibitors, Combination Products

What Upcoming Trends Are Expected To Impact The Proteasome Inhibitors Market Globally?

Growing investments are a prominent trend emerging in the proteasome inhibitors market. The primary businesses in this sector are focusing on the investment, development, and commercialization of proteasome inhibitors, which are instrumental in furthering research and introducing novel treatments into the market. Case in point, in September 2022, QLi5 Therapeutics GmbH, a German company that works on new classes of proteasome inhibitors, obtained an investment of $10.96 million (EUR 10 million) from South Korean venture capital firm SV Investment, alongside Germany’s KHAN Technology Transfer Fund I, and South Korean firms Atinum Investment Co., Ltd. and Daol Investment & Securities Co., Ltd. The aim behind this funding is the development of innovative proteasome inhibitors for treating cancer and inflammatory and autoimmune diseases. This financial boost will expedite QLi5’s pipeline of unique proteasome inhibitors to the commencement of clinical studies that address numerous health issues.

Which Companies Play A Key Role In The Development Of The Proteasome Inhibitors Market?

Major companies operating in the proteasome inhibitors market include Pfizer Inc., Johnson And Johnson, AbbVie, Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Fresenius Kabi AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Sigma-Aldrich, Zydus Pharmaceuticals, Onyx Pharmaceuticals Inc., Tocris Bioscience, Accuitis Inc., TG Therapeuticsn Inc., QLi5 Therapeutics GmbH, Progenra Inc., Nurix Inc., Cephalon Inc., Cleave Therapeutics, Lifesensors Inc., MimiVax LLC, Apotex Inc.

https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report

What Are The Key Regional Developments Shaping The Proteasome Inhibitors Market?

North America was the largest region in the proteasome inhibitors market in 2024. The regions covered in the proteasome inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12251&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model